Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Novo Nordisk ADR’s stock clocked out at $47.99, up 0.88% from its previous closing price of $47.57. In other words, the price has increased by $0.88 from its previous closing price. On the day, 18.43 million shares were traded. NVO stock price reached its highest trading level at $48.24 during the session, while it also had its lowest trading level at $47.37.
Ratios:
To gain a deeper understanding of NVO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 31.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.16. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.52.
Morgan Stanley Downgraded its Equal-Weight to Underweight on September 29, 2025, while the target price for the stock was maintained at $47.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 213242593280 and an Enterprise Value of 281873580032. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.98, and their Forward P/E ratio for the next fiscal year is 13.32. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.46 while its Price-to-Book (P/B) ratio in mrq is 7.97. Its current Enterprise Value per Revenue stands at 0.893 whereas that against EBITDA is 1.703.
Stock Price History:
The Beta on a monthly basis for NVO is 0.67, which has changed by -0.57055163 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $112.52, while it has fallen to a 52-week low of $43.08. The 50-Day Moving Average of the stock is -7.85%, while the 200-Day Moving Average is calculated to be -23.95%.
Shares Statistics:
It appears that NVO traded 16.59M shares on average per day over the past three months and 22322330 shares per day over the past ten days. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.03% stake in the company. Shares short for NVO as of 1763078400 were 27691852 with a Short Ratio of 1.67, compared to 1760486400 on 26671758. Therefore, it implies a Short% of Shares Outstanding of 27691852 and a Short% of Float of 0.8200000000000001.
Dividends & Splits
With its trailing 12-month dividend rate of 11.65, NVO has a forward annual dividend rate of 1.73. Against a Trailing Annual Dividend Yield of 0.24490224. The stock’s 5-year Average Dividend Yield is 1.58. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-08-18 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
Its stock is currently analyzed by 3.0 different market analysts.
Analysts are recommending an EPS of between $24.69 and $22.59 for the fiscal current year, implying an average EPS of $23.08. EPS for the following year is $21.94, with 5.0 analysts recommending between $22.74 and $21.29.
Revenue Estimates
In. The current quarter, 9 analysts expect revenue to total $77.29B. It ranges from a high estimate of $82.65B to a low estimate of $72.74B. As of. The current estimate, Novo Nordisk ADR’s year-ago sales were $85.68BFor the next quarter, 9 analysts are estimating revenue of $76.16B. There is a high estimate of $76.16B for the next quarter, whereas the lowest estimate is $76.16B.
A total of 19 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $314.87B, while the lowest revenue estimate was $302.66B, resulting in an average revenue estimate of $307.74B. In the same quarter a year ago, actual revenue was $290.4BBased on 20 analysts’ estimates, the company’s revenue will be $307.46B in the next fiscal year. The high estimate is $338.7B and the low estimate is $286.77B.
